Cases

Search for a case

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Cases

June 26, 2024

Sharecare, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sharecare, Inc. (“Sharecare” or the “Company”) (NASDAQ:SHCR), in connection with its acquisition by Altaris, LLC. Under the merger agreement, the Company’s shareholders will receive $1.43 per share.

Join Case →

June 26, 2024

Alimera Sciences, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. (“Alimera” or the “Company”) (NASDAQ: ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company’s shareholders will receive $5.50 per share cash at closing and one non-tradable contingent value right (“CVR”) to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.

Join Case →

June 7, 2024

PowerSchool Holdings, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of PowerSchool Holdings, Inc. (“PowerSchool” or the “Company”) (NYSE: PWSC), in connection with its acquisition by Bain Capital, LP. Under the merger agreement, the Company’s shareholders will receive $22.80 per share. The transaction is valued at approximately $5.6 billion.

Join Case →

May 9, 2024

DecisionPoint Systems, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of DecisionPoint Systems, Inc. (“DecisionPoint” or the “Company”) (NYSE: DPSI), in connection with its acquisition by affiliates of Barcoding Holdings, LLC. Under the merger agreement, the Company’s shareholders will receive $10.22 per share.

Join Case →

May 9, 2024

Deciphera Pharmaceuticals, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Deciphera Pharmaceuticals, Inc. (“Deciphera” or the“Company”) (NASDAQ: DCPH), in connection with its acquisition by ONO Pharmaceutical, Co., Ltd. via tender offer. Under the merger agreement, the Company’s shareholders will receive $25.60 per share.

Join Case →

May 9, 2024

U.S. Silica Holdings, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of U.S. Silica Holdings, Inc. (“U.S. Silica” or the “Company”) (NYSE: SLCA), in connection with its acquisition by affiliates of Apollo Global Management, Inc. (NYSE: APO). Under the merger agreement, the Company’s shareholders will receive $15.50 per share. The transaction is valued at approximately $1.85 billion.

Join Case →

April 5, 2024

Shockwave Medical, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Shockwave Medical, Inc. (“Shockwave” or the “Company”) (NASDAQ: SWAV), in connection with its acquisition by Johnson & Johnson (NYSE: JNJ). Under the merger agreement, the Company’s shareholders will receive $335.00 per share. The transaction is valued at approximately $13.1 billion.

Join Case →

April 4, 2024

ChampionX Corporation Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) in connection with its acquisition by Schlumberger Limited (“Schlumberger”)(NYSE: SLB). Under the terms of the merger agreement, the Company’s shareholders will receive 0.735 shares of Schlumberger common stock for each share of ChampionX common stock owned, representing implied per-share consideration of $40.32 based upon Schlumberger’s April 3, 2024 closing price of $54.86.

Join Case →

April 4, 2024

Endeavor Group Holdings, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Endeavor Group Holdings, Inc. (“Endeavor Group” or the “Company”) (NYSE: EDR), in connection with its acquisition by Silver Lake. Under the merger agreement, the Company’s shareholders will receive $27.50 per share.

Join Case →

We will fight for you and have your back no matter what. Join the tens of thousands of people we’ve helped.

Cases

Search for a case

Cases

Sharecare, Inc. Investigation

Alimera Sciences, Inc. Investigation

PowerSchool Holdings, Inc. Investigation

DecisionPoint Systems, Inc. Investigation

Deciphera Pharmaceuticals, Inc. Investigation

U.S. Silica Holdings, Inc. Investigation

Shockwave Medical, Inc. Investigation

ChampionX Corporation Investigation

Endeavor Group Holdings, Inc. Investigation

Where to find us?

new york

california

georgia

NEW JERSEY